All In MedTech

FDA Clearance Tracker · P190032-S015

FoundationOne Liquid CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 14, 2024

Approved

Time to decision

379 days

Received Nov 1, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P190032-S015
Device name
FoundationOne Liquid CDx
Applicant location
Boston, MA
Received
Nov 1, 2023
Decided
Nov 14, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P190032

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval order to expand the intended use of FoundationOne Liquid CDx (F1LCDx) (P190032/S015) to include a companion diagnostic indication to identify patients with non-small cell lung cancer harboring MET single nucleotide variants (SNVs) and insertions and deletions (indels) that lead to MET exon 14 skipping alterations who are eligible for treatment with Tepmetko® (tepotinib).

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.